🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Triaging chest pain patients can be challenging. Dr Brendan Adler shared his experience with intelligent workflows and more in his presentation on 'Building AI into your Radiology Practice' at AHRA 2022. View full the presentation here: vimeo.com/733097925/12a8…

Artrya is delighted to announce the appointment of Dr Jacque Sokolov to the Artrya Board as a non-executive director. Dr Sokolov will be an important contributor as Artrya executes growth priorities and pursues regulatory clearance. hubs.la/Q01j0XgC0

It's live! We are so excited to announce that the new Artrya website has just launched. Access it now: artrya.com

August 4th marked an exciting milestone in the Artrya journey, as the Hon Roger Cook MLA, Deputy Premier of WA, officially opened our new office in Perth. We are proud to be a Western Australian-based global MedTech company and look forward to continuing to grow in this space.

The Artrya team are looking forward to attending CSANZ on the Gold Coast, our first in-person Australian conference! Visit our team for a Salix demonstration. #CSANZ2022 Salix Coronary Anatomy is entered on the Australian Register of Therapeutic Goods, (ARTG 347719).

Prof Benjamin Chow outlined the limitations of spatial resolution and explained that early areas of plaque development and progression are difficult to visualise with CT, leading to smaller volumes of plaque potentially being missed. Full presentation: hubs.la/Q01jjdhg0

Artrya shares a report by Senior Analyst Tom Godfrey from MST Access. The ‘At the heart of coronary artery disease’ report values Artrya at $1.44 per share. Highlights: capital light, scalable business model, with compelling technology. Access here: hubs.la/Q01kcnXB0

Now published in European Radiology, 'Evaluation of an artificial intelligence coronary artery calcium scoring model from computed tomography' discusses our novel AI-based automated solution. Access here: link.springer.com/content/pdf/10… Abdul Ihdayhid Dr Girish Dwivedi Artrya Harry Perkins Institute

Artrya MD, John Barrington AM, joined colleagues at the Harry Perkins Institute of Medical Research & local WA community members to discuss the leading innovations improving health outcomes for patients with coronary disease. Watch now: lnkd.in/gyeErwDM Harry Perkins Institute

MST Access has released an Update Report on Artrya Ltd noting their forecasts remain largely unchanged and that MST’s company valuation of Artrya remains at $1.44 per share. Access here: hubs.la/Q01lQ0zl0

We were pleased to host a Health and Medical Life Sciences forum at Artrya last night. Initiated by Governor Kim Beazley AC, leaders from the sector met to discuss sector development in Western Australia.

MST Access has provided an update report on Artrya, following our ASX quarterly update. MST noted our sharper focus, refined strategy and valued our shares at $1.35. You can read the report here: hubs.la/Q01qlmRP0

$AYA Artya set to market Salix V2.0 Software into Europe tinyurl.com/2a9cmcy4 Artrya #AYA #ASX #ASXNews

Artrya announced today it has received regulatory approval for its Salix Coronary Anatomy (SCA) product in Europe. Managing Director and CEO John Barrington AM said this was an important moment for the company. View full announcement: hubs.la/Q01qQgMQ0

Artrya's Managing Director and CEO John Barrington AM discussing the company's CE Mark European regulatory approval. View the full interview here: hubs.la/Q01qWX4z0

Artrya announced today that it has received regulatory approval for its Salix Coronary Artery (SCA) product in the United Kingdom. View full announcement: hubs.la/Q01rBr3H0

Proactive has reported on Artrya’s success in gaining United Kingdom regulatory approval for our Salix Coronary Anatomy product. Read the report here: hubs.la/Q01rBC7F0

Artrya Managing Director and CEO John Barrington AM shares some insights on Artrya’s journey so far with the Startup West podcast.

Artrya is in a strong capital position to continue product development and seek FDA approval following approvals already gained in Australia, New Zealand, European Union and the United Kingdom.

Artrya is in a strong cash position to exploit the power of AI in addressing the largest cause of death in the world – heart disease.